Amarantus BioSciences

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. It focuses on developing orphan drug-designated therapeutic products in the fields of neurology, psychiatry, ophthalmology, regenerative medicine, and neurology diagnostics. The company's primary therapeutic candidate, eltoprazine, is a small molecule for the treatment of levodopa-induced dyskinesia. Its diagnostic division is dedicated to the development and commercialization of neurological diagnostic products. LymPro Test, its diagnostic product, is a blood-based test for diagnosing Alzheimer's disease.